Gilead Sciences reached a $246.8 million class action lawsuit settlement with direct purchasers of its HIV medications over allegations it made a deal with Teva Pharmaceuticals to delay generic versions of the drugs, Law360 reports.
On Aug. 9, the direct purchaser plaintiffs filed a motion in California federal court seeking preliminary approval of the Gilead Sciences settlement resolving allegations they overpaid for HIV drugs Atripla and Truvada between February 2018 and September 2022.
The motion states the parties reached the settlement after “years of hard-fought litigation” and negotiations. They reportedly reached a final agreement July 24.
Read more at News.law
